Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 9/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.53 |
| ▸ | NPY1R | P25929 | 7/20 | 0.53 |
| ▸ | NPY2R | P49146 | 5/20 | 0.53 |
| ▸ | IL23R | Q5VWK5 | 9/20 | 0.53 |
| ▸ | TFPI | P10646 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30184178 | 0.91 | NPY4R (0.53) | NPY4RNPY5RNPY1RNPY2RIL23R | |
| SCHEMBL30168754 | 0.90 | IL23R (0.58) | IL23RTFPI | |
| SCHEMBL30865068 | 0.90 | TFPI (0.58) | NPY4RNPY5RNPY1RNPY2RIL23R | |
| SCHEMBL30865071 | 0.89 | TFPI (0.61) | NPY4RNPY5RNPY1RNPY2RIL23R | |
| SCHEMBL30865075 | 0.88 | TFPI (0.60) | NPY4RNPY5RNPY1RNPY2RIL23R | |
| SCHEMBL30184327 | 0.88 | TFPI (0.60) | NPY4RNPY5RNPY1RNPY2RIL23R | |
| SCHEMBL29895842 | 0.87 | NPY4R (0.55) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL30345254 | 0.86 | NPY4R (0.58) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL31458901 | 0.86 | NPY4R (0.53) | NPY4RNPY5RNPY1RNPY2RIL23R | |
| SCHEMBL29518715 | 0.86 | NPY4R (0.56) | NPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551537-B2 | Methods and compositions for the treatment and prevention of type 1 diabetes | DR. MARY MORRIS & ASSOCIATES, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-20240041986-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF TYPE 1 DIABETES | DR. MARY MORRIS & ASSOCIATES, LLC (US) | 2024-02-08 | — | — | US | disclosed |
| US-20230018324-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF TYPE 1 DIABETES | DR. MARY MORRIS & ASSOCIATES, LLC (US) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551537-B2 | Methods and compositions for the treatment and prevention of type 1 diabetes | IAPP, GLP1R, SLC5A1 | NPY4R 329/4885NPY5R 256/4885NPY1R 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.